Sysmex Corporation ADR (OTCMKTS:SSMXY) Sees Significant Drop in Short Interest

Sysmex Corporation ADR (OTCMKTS:SSMXY) was the recipient of a large decrease in short interest during the month of January. As of January 15th, there was short interest totaling 127,705 shares, a decrease of 53.9% from the December 31st total of 277,294 shares. Based on an average daily volume of 698,584 shares, the short-interest ratio is currently 0.2 days. Approximately 0.0% of the shares of the company are short sold. Approximately 0.0% of the shares of the company are short sold. Based on an average daily volume of 698,584 shares, the short-interest ratio is currently 0.2 days.

Sysmex Stock Up 1.2%

SSMXY opened at $9.45 on Friday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.49 and a current ratio of 3.34. The company has a market capitalization of $5.95 billion, a PE ratio of 18.90 and a beta of 1.13. The stock’s fifty day moving average is $9.74 and its 200-day moving average is $11.83. Sysmex has a one year low of $9.00 and a one year high of $19.85.

Sysmex (OTCMKTS:SSMXY) last announced its earnings results on Wednesday, November 5th. The company reported $0.16 earnings per share for the quarter, meeting the consensus estimate of $0.16. Sysmex had a return on equity of 9.86% and a net margin of 9.32%.The business had revenue of $826.60 million during the quarter, compared to analysts’ expectations of $880.80 million. On average, equities analysts predict that Sysmex will post 0.57 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, The Goldman Sachs Group upgraded Sysmex from a “hold” rating to a “buy” rating in a research report on Thursday, October 9th. One research analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy”.

About Sysmex

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.